Sheppard C, Collins L, Fiorentino D, Fracchia J, Merlis S.
Polypharmacy in psychiatric treatment. Incidence at a state hospital. Curr Therap Res
1969; 11: 765–74.
Keks NA, Alston K, Hope J, Krapivensky N, Culhane C, Tanaghow A, et al. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry
1999; 33: 896–901.
Ito C, Kubota Y, Sato M.
A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci
1999; 53 (suppl): S35–40.
Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry
2008; 69: 240–5.
Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
J Clin Psychiatry
1999; 60: 425–6.
Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand
2002; 106: 323–30.
National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. Clinical Practice Algorithms and Pathways to Care. NICE, 2002.
British Medical Association, Royal Pharmaceutical Society. British National Formulary, March issue. BMJ Books & Pharmaceutical Press, 2008.
Taylor D, Paton C, Kerwin R.
The Maudsley Prescribing Guidelines (9th ed). Informa, 2007.
Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry
2005; 162: 130–6.
Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry
1997; 171: 569–73.
Kotler M, Stous RD, Reznik I, Shwartz S, Weizman A, Spivak B.
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. Int Clin Psychopharmacol
2004; 19: 23–6.
Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med
2006; 354: 472–82.
Yagcioclu AE, Akbdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry
2005; 66: 63–72.
Gibson A, Patel NC, Lauriello J, Buckley P.
Anti-psychotic combinations: blind step or logical?
2008; 7: 41–8.
Taylor D, Mir S, Mace S, Whiskey E.
Co-prescribing of atypical and typical antipsychotics – prescribing sequence and documented outcome. Psychiatr Bull
2002; 26: 170–2.
Correll C, Frederickson A, Kane J, Manu P.
Does antipsychotic polypharmacy the risk for metabolic syndrome?
2007; 89: 91–100.
The use of high-dose antipsychotic medication. Br J Psychiatry
1994; 164: 448–58.
Sernyak MJ, Rosenheck R.
Clinicians' reasons for antipsychotic co-prescribing. J Clin Psychiatry
2004; 65: 1597–600.
Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull
2002; 28: 105–9.
Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N.
Combination antipsychotic therapy in clinical practice. Psychiatr Serv
2003; 54: 55–9.
Waddington JL, Yousseff HA, Kinsella A.
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry
1998; 173: 325–9.
Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry
2004; 65: 715–20.
Ray W, Chung C, Murray KT, Hall K, Stein M.
Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med
2009; 360: 225–35.
Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavkan J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up study. BMJ
2006; 333: 224–30.
Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis
2004; 192: 19–27.
Bralet MC, Yon V, Loas G, Noisette C.
Cause of mortality in schizophrenic patients: prospective study of years of a cohort of 150 chronic schizophrenic patients. Encephale
2000; 26: 32–41.
Noncompliance in community psychiatry: a review of clinical interventions. Hosp Community Psychiatry
1991; 42: 282–7.
Joukamaa M, Heliövaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V.
Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry
2006; 188: 122–7.
Suzuki T, Uchida H, Tanaka K, Nomura K, Takano H, Tanabe A, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol
2004; 7: 133–42.
Suzuki T, Uchida H, Watanabe K, Yagi G, Kashima H.
A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
2004; 28: 361–9.
Kawai NA, Yamakawa YB, Matsuzaka HA, Baba HA, Tachikawa AC, Hori HD, et al. Switching from high-dose of multiple neuroleptic treatments to the single atypical neuroleptic regimen (the second report): What are the risks for psychotic exacerbations?
Int Clin Psychopharmacology
2005; 20: A15.
Soni SD, Sampath G, Shah A, Krska J.
Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand
1992; 85: 354–9.